(NASDAQ: SCYX) Scynexis's forecast annual revenue growth rate of 71.09% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 37.1%, and it is also forecast to beat the US market's average forecast revenue growth rate of 22.74%.
Scynexis's revenue in 2025 is $2,932,000.On average, 5 Wall Street analysts forecast SCYX's revenue for 2026 to be $1,644,652,588, with the lowest SCYX revenue forecast at $50,442,000, and the highest SCYX revenue forecast at $3,331,983,640. On average, 5 Wall Street analysts forecast SCYX's revenue for 2027 to be $122,286,179, with the lowest SCYX revenue forecast at $80,321,121, and the highest SCYX revenue forecast at $165,720,014.
In 2028, SCYX is forecast to generate $616,172,947 in revenue, with the lowest revenue forecast at $268,744,231 and the highest revenue forecast at $913,285,557.